Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | ALPL | P05186 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18530465 | 0.89 | SMN1; SMN2 (0.79) | SMN1; SMN2LMNAKMT2AMEN1ALOX12 | |
| SCHEMBL14018775 | 0.85 | ALPL (0.59) | SMN1; SMN2LMNAKMT2AALPLGAA | |
| SCHEMBL8278300 | 0.85 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNAKMT2AMEN1ALOX12 | |
| SCHEMBL7535714 | 0.83 | SMN1; SMN2 (0.72) | SMN1; SMN2LMNAKMT2AMEN1ALOX12 | |
| SCHEMBL95715 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2LMNAKMT2AMEN1ALOX12 | |
| SCHEMBL7529463 | 0.83 | TP53 (0.80) | SMN1; SMN2LMNAKMT2AMEN1ALOX12 | |
| SCHEMBL7528115 | 0.83 | SMN1; SMN2 (0.72) | SMN1; SMN2LMNAKMT2AMEN1ALOX12 | |
| SCHEMBL5962533 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2LMNAKMT2AMEN1ALOX12 | |
| SCHEMBL7536903 | 0.83 | LMNA (0.75) | SMN1; SMN2LMNAKMT2AMEN1ALOX12 | |
| SCHEMBL10576738 | 0.83 | ALDH1A1 (0.50) | SMN1; SMN2LMNAKMT2AMEN1ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183393-A1 | Inhibitors of Rho C | ICONIX PHARMACEUTICALS INC. | 2002-12-05 | — | — | US | disclosed |
| WO-2002022565-A1 | INHIBITORS OF RHO C | ICONIX PHARMACEUTICALS, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183393-A1 | Inhibitors of Rho C | RHOC, ROCK1, RHOA | SMN1; SMN2 2961/4885LMNA 2037/4885KMT2A 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.